In EGFR-TKI-resistant NSCLC cells, an RNA interference-mediated ADAM17 knockdown recovers the sensitivity to the EGFR-TKI gefitinib through the dephosphorylation of EGFR [128]. This evidence concerns the gene ADAM17 and non-small cell lung carcinoma.